MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook
StockNews.AI · 2 hours
AI Summary
MiniMed reported a strong FY2026 with $3.102B in revenue, marking a record year and robust international growth. The company advanced its pipeline with FDA/CE clearances and launches (Flex, 780G with Instinct, and MiniMed Go MDI) and issued a FY27 outlook of about 10% organic revenue growth and ~16% Adjusted EBITDA margin, aided by an extra week in the year. Near-term catalysts include U.S./EU launches and Abbott sensor partnerships.
Sentiment Rationale
Record FY26 sales, solid international growth, and a clear 10% organic growth guide with a 16% EBITDA target, plus multiple near-term catalysts (Flex/Go/780G) and Abbott sensor partnerships, collectively imply favorable near-term price action.
Trading Thesis
Bullish on MMED over 6–12 months as new devices monetize and international adoption accelerates.
Market-Moving
- Regulatory approvals and Go/Flex launches provide near-term revenue tailwinds.
- FY27 organic growth target ~10% supports multiple expansion potential.
- International growth remains the core driver; international sales up ~20.6%.
- Abbott dual sensor collaboration extension could lift CGM attachments and services.
Key Facts
- Q4 net sales $837M, up 15.6%; FY26 $3.102B, up 14.2%.
- International net sales $2.185B, up 20.6%; U.S. net sales $917M, up 1.5%.
- FDA/CE clearances and launches: Flex, 780G with Instinct; Go MDI expanding.
- FY27 outlook: ~10% organic growth; Adjusted EBITDA margin ~16%; extra year adds 1-1.5%.
- Pumps: ~145k FY26; 659k pump users; CGM attachment 66%.
Companies Mentioned
- MiniMed Group Inc (MMED): Reported strong results; launches of Flex and Go Smart MDI; FY27 guidance supports growth.
- Abbott Laboratories (ABT): Supplies Simplera/Instinct CGMs; extension of dual glucose-ketone sensor collaboration could boost CGM attachments and services.
Earnings
Earnings release reflecting pipeline progress and a constructive FY27 outlook; relevant for MMED valuation and growth trajectory.